Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avalon GloboCare (ALBT) Research & Development (2018 - 2023)

Avalon GloboCare's Research & Development history spans 6 years, with the latest figure at -$542.0 for Q4 2023.

  • For Q4 2023, Research & Development fell 100.29% year-over-year to -$542.0; the TTM value through Dec 2023 reached $109618.0, down 85.01%, while the annual FY2023 figure was $109618.0, 85.01% down from the prior year.
  • Research & Development reached -$542.0 in Q4 2023 per ALBT's latest filing, down from $17810.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $949711.0 in Q2 2019 to a low of -$554730.0 in Q4 2021.
  • Average Research & Development over 5 years is $190947.0, with a median of $208920.0 recorded in 2020.
  • Peak YoY movement for Research & Development: soared 361006.84% in 2019, then crashed 365.52% in 2021.
  • A 5-year view of Research & Development shows it stood at $414559.0 in 2019, then plummeted by 49.6% to $208920.0 in 2020, then plummeted by 365.52% to -$554730.0 in 2021, then soared by 134.21% to $189762.0 in 2022, then tumbled by 100.29% to -$542.0 in 2023.
  • Per Business Quant, the three most recent readings for ALBT's Research & Development are -$542.0 (Q4 2023), $17810.0 (Q2 2023), and $92350.0 (Q1 2023).